Publications
Sex and sex steroids as determinants of cardiovascular risk
A. Cignarella, C. Bolego, M. Barton
Steroids 2024
Post-transcriptional and epigenetic regulation of estrogen signaling
A. Cignarella, C. Boscaro, M. Albiero, C. Bolego, M. Barton
J Pharmacol Exp Ther 386, 288-297, 2023
The G protein-coupled estrogen receptor GPER in physiology and disease - an update
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 19, 407-424, 2023
Consensus Document: Challenges in the evaluation of endothelial cell function - a statement from the European Society of Hypertension Working Group on Endothelins and Endothelial Factors
G.P. Rossi, M. Barton, N. Dhaun, D. Rizzoni, T.M. Seccia
J Hypertens 41, 369-379, 2023
Endothelium and endothelin: regulators of arterial stiffness and fibrinolysis in ANCA-associated vasculitis
M. Barton
Kidney Int 102, 963-966, 2022
Efficacy and safety of angiogenesis inhibitors: sex differences and current challenges
A. Cignarella, G.P. Fadini, C. Bolego, L. Trevisi, C. Boscaro, V. Sanga, T.M. Seccia, A. Rosato, G.P. Rossi, M. Barton
Cardiovasc Res 118, 988-1003, 2022 (Editor's Choice)
Serum from patients with severe alcoholic liver cirrhosis inhibits proliferation and migration of human coronary artery smooth muscle cells
M. Mechelinck, M. Peschel, M. A. Habigt, D. Kroy, M. Lehrke, M. J. Helmedag, R. Rossaint, M. Barton, M. Hein
J Clin Med 10, 5471, 2021
Paul M. Vanhoutte: Mind, Mensch, and Mentor
M Barton.
J Cardiovasc Pharmacol 78, 91, 2021
In Memoriam: Christian Sauter
H. Ruh, M. Barton
Endocrin Metab Sci 5, 100115, 2021
Steroid Hormones and Receptors in Health and Disease: A Research Conference Co-Organized by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH), May 25-27, 2021
M. Barton, D.E. Frigo, Z. Madak-Erdogan, F. Mauvais-Jarvis, E.R. Prossnitz
FASEB J 35, e21858, 2021
Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: a large-scale, cross-sectional study in primary care
Y. Rachamin, T. Grischott, T. Rosemann, M.R. Meyer.
Atherosclerosis 324, 141-147, 2021
Chronic coronary syndromes in women
M.R. Meyer
Mayo Clinic Proceedings 96, 1058-1070, 2021
Obesity, diabetes and cardiovascular risk: how to disrupt a vicious circle
C. Cardillo, M. Barton
Endocrin Metab Sci 2, 100081, 2021
Efficacy and safety of abbreviated eptifibatide treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
F. Fischer, S. Buxy, D.J. Kurz , F.R. Eberli, O. Senn, R. Zbinden, U. Held, M.R. Meyer.
Am J Cardiol 139,15-21, 2021
Exercise is medicine – key to cardiovascular disease and diabetes prevention
M. Barton, C. Cardillo
Cardiovasc Res 117, 360-364, 2021
Role of perivascular adipose tissue for sex differences in coronary artery disease and spontaneous coronary artery dissection (SCAD)
M.R. Meyer, M. Barton
Endocrin Metab Sci 2, 100068, 2021
Differences in presentation and clinical outcomes between left or right bundle branch block and ST segment elevation in patients with acute myocardial infarction
M.R. Meyer, D. Radovanovic, G. Pedrazzini, H. Rickli, M. Roffi, T. Rosemann, F.R. Eberli, D.J. Kurz
Eur Heart J Acute Cardiovasc Care 9, 848-856, 2020
In memoriam: Tomoh Masaki
N. Emoto, M. Yanagisawa, M. Barton
Hypertension 76, 1664-1666, 2020
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
G.P. Rossi, V. Sanga, M. Barton
eLife 9, e57278, 2020
Heart failure with preserved ejection fraction in women - new clues to causes and treatment
M. Barton, M.R. Meyer
JACC Basic Transl Sci 5, 296-299, 2020
Early life stress determines insulin signaling in adulthood
M. Barton, E.R. Prossnitz
J Physiol 598, 427-428, 2020
Linking regulation of nitric oxide to endothelin-1: the Yin and Yang of vascular tone in the atherosclerotic plaque
R.M. Gupta, P. Libby, M. Barton
Atherosclerosis 292, 201-203, 2020
In memoriam: Paul M. Vanhoutte
M. Barton, C. Cardillo
J Physiol 597, 5731-5737, 2019
Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019
(featured in: Hypertension Editors’ Picks: Pulmonary Hypertension
Hypertension 77, e1–e10, 2021)
Nox1 downregulators: a new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019
Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia (letter)
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science 365, eaav9518, 2019
Primum non nocere: why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019
Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population.
Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T
Clin Ther 41, 107-117, 2019
Permissive role for GPER in arterial hypertension
M. Barton, M.R. Meyer
Hypertension 73, e9-e10, 2019
HuR-ry up: How hydrogen sulfide protects against atherosclerosis
M. Barton, M.R. Meyer
Circulation 139, 155-118, 2019
Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 8, 283-290, 2019
Self-experimentation and serendipity: how cardiac catheterization led the way to coronary balloon angioplasty
M. Barton
BMJ 363:k5006, 2018
GPER is required for age-dependent albuminuria and glomerulosclerosis: evidence for its role in podocyte injury and mesangial Nox1 regulation
M.R. Meyer, C. Daniel, C.D. Woods, G. Sharma, N.C. Fredette, K. Amann, M. Barton, E.R. Prossnitz
Hypertension 72 (suppl), P261, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018
Hypertrophe und dilatative Kardiomyopathie
M.R. Meyer, F.R. Eberli.
Swiss Medical Forum 18, 168–177, 2018
In Memoriam: Sidney George Shaw, DPhil (1948-2017)
M. Barton, H. J. Little, R.D. Vaughn-Jones, S. Daniels, M.R. Dashwood, M.R. Dashwood, J.C. Tsui.
Physiol Res 67 (Suppl. 1), S-27-S35, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. a Joint Consensus Statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertens 36, 462-471, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. a Joint Consensus Statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertens 36, 451-461, 2018
Role of GPER in estrogen-dependent nitric oxide formation and vasodilation.
N.C. Fredette, M.R. Meyer, E.R Prossnitz
J Steroid Biochem Mol Biol 76, 65-72, 2018
GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton
J Steroid Biochem Mol Biol 176, 82-87, 2018
Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018
Iron substitution in the treatment of chronic heart failure
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 23; w14453, 2017
Paradoxical lack of increase in endothelin-1 levels in obese mice – possible role of endothelin-B receptors
O. Baretella, S.K. Chung, A. Xu, P.M Vanhoutte
Acta Pharmacologica Sinica 38, 1699–1700, 2017
Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017
GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017
Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016
Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016
Efficacy and safety of transcatheter closure in adults with large or small atrial septal defects
M.R. Meyer, D.J. Kurz, A.M. Bernheim, O. Kretschmar. F.R. Eberli
Springerplus 5, 1841, 2016
Obesity causes lymphatic vascular injury: time for clinical translation
Barton M, Husmann M.
J Physiol 594, 6807-6808, 2016
Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016
Not lost in translation: emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016
GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016
Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016
G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015
Erratum: G protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 5, 13510, 2015
Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015
Nicolaus Copernicus and the rapid vascular responses to aldosterone
M. Barton, M.R. Meyer
Trends Endocrinol Metab 26, 396-398, 2015
Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015
Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015
Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014
Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 4, 7564, 2014
In memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014
Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014
25 Years of endothelin research: the next generation
N. Emoto, N. Vignon-Zellweger, R.A. Lopes, J. Cacioppo, L. Debiens, D. Kamato, T. Leurgans, R. Moorhouse, J. Straube, R. Wurm, S. Heiden, A. Ergul, M. Yanagisawa, M. Barton
Life Sci 118, 77-86, 2014
Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014
Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014
Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretella, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci 118, 206-212, 2014
Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz
Life Sci 118, 226-231, 2014
Estrogen biology: new insights on GPER function and clinical opportunities
E.R Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014
Regulation of vascular smooth muscle tone by Adipose-Derived Contracting Factor
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
PLoS ONE 8, e79245, 2013
Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013
Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz
J Cardiovasc Pharmacol 62, 22-25, 2013
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013
Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton
Curr Opin Pharmacol 13, 149-153, 2013
Cholesterol and atherosclerosis: modulation by estrogen
M. Barton
Curr Opin Lipidol 24, 214-220, 2013
Themed section: endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013
Endothelin XII - Editorial
M. Barton, M. Yanagisawa, P.M. Vanhoutte, T. Masaki
Life Sci 91, 449-451, 2012
The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
M. Barton, A.P. Davenport
Life Sci 91, 462-465, 2012
The First Tomoh Masaki Award (2011)
M. Barton, N. Emoto, T. Miyauchi
Life Sci 91, 466-469, 2012
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton
Life Sci 91, 528-539, 2012
The future of endothelin research: scientific mentoring and beyond
M. Barton, D.M. Pollock
Life Sci 91, 470-474, 2012
GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz
Life Sci 91, 623-627, 2012
Testosterone and secondary hypertension: new pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer
Hypertension 59, 1011-1103, 2012
Position paper: the membrane estrogen receptor GPER - clues and questions
M. Barton
Steroids 77, 925-242, 2012
Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin Kidney J 5, 17-27, 2012
Endothelin receptor antagonists in cardiovascular medicine: challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012
Deletion of the G protein-coupled estrogen receptor increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L. Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz
Hypertension 59, 507-512, 2012
Childhood obesity: a life-long health risk
M. Barton
Acta Pharmacol Sin 33, 189-193, 2012
Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Endothelin in renal physiology and disease
Contrib Nephrol 172 (M. Barton, D.E. Kohan, Eds), Karger, Basel, 1-266, 2011
The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton
Vascul Pharmacol 55, 17-25, 2011
Endothelin antagonists in clinical trials: lessons learned
M. Barton, D.E. Kohan
Contrib Nephrol 172, 255-260, 2011
Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib Nephrol 172, 120-138, 2011
Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton
Contrib Nephrol 172, 210-222, 2011
Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011
GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton
Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011
Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011
The discovery of endothelium-dependent contraction: the legacy of Paul M. Vanhoutte
M. Barton
Pharmacol Res 63, 455-462, 2011
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010
Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflügers Arch Eur J Physiol 460, 825-837, 2010
Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010
Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010
Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010
Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010
Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
ERα, ERβ, and gpER: novel aspects of estrogen receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83, 605-610, 2009
Non-genomic regulation of vascular cell function and growth by estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 308, 9-16, 2009
Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins Other Lipid Mediat 89, 89-97, 2009
Regulatory role of G protein coupled estrogen receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C. Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut, R. Minotti, M.R. Meyer, K. Amann, E. Ammann, A. Perez-Dominguez, M. Genoni, D.J. Clegg, N.J. Dun, T.C. Resta, E.R. Prossnitz, M. Barton
Circ Res 104, 288-291, 2009
Getting radical about obesity: new links between fat and heart disease
M. Barton, E. Haas, I. Bhattacharya
Arterioscler Thromb Vasc Biol 29, 447-448, 2009
Morbus Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B. Senn
Swiss Medical Forum 9, 487-488, 2009
Endothelin - Twenty years from discovery to therapy
Matthias Barton, Masashi Yanagisawa
Can J Physiol Pharmacol 86, 485-498, 2008
Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008
Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend Med 5 (Suppl. A), S19-S33, 2008
Regional heterogeneity of functional changes in conduit arteries after high-fat diet
I. Bhattacharya, A.L. Mundy, C.C. Widmer, M. Kretz, M. Barton
Obesity (Silver Spring) 16, 743-748, 2008
Schwere Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I. Bopp-Kistler
Praxis (Bern 1994) 97, 1137-1141, 2008
Fat intake and cardiovascular response
M. Damjanovic, M. Barton
Curr Hypertens Rep 10, 25-31 2008
Inflammation and atherosclerosis
M. Barton, R. Minotti, E. Haas
Circ Res 101, 750-751, 2007
Selective activation of G protein-coupled estrogen receptor GPR30 inhibits vasoconstriction and induces vascular smooth muscle cell ERK1/2 phosphorylation
I. Bhattacharya, M. Damjanovic, S. Hirsiger, E. Haas, A. Gut, L. Mueller-Guerre, R. Henggeler, R. Minotti, E.R. Prossnitz, M. Barton
Circulation 116, II74, 2007
Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007
WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J Rapid Response, e-pub August 28, 2007
Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Distinct roles of estrogen receptors α and β mediating acute vasodilatation of epicardial coronary arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, M. Barton
Hypertension 49, 1364-1370, 2007
Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007
Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007
Impaired vascular function in normoglycemic mice prone to autoimmune diabetes: role of nitric oxide
T. Traupe, P.C. Nett, B. Frank, L. Tornillo, R. Hofmann-Lehmann, L.M. Terracciano, M. Barton
Eur J Pharmacol 557,161-167, 2007
Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007
Vaskuläre Interaktion zwischen Insulin und LDL Cholesterin
E. Haas, R. Minotti, C. Raselli, A. Hoehn, M. Barton
Dtsch Med Wochensch 132, 20, 2007
Endothelin stimulates vascular hydroxyl radical formation: effect of obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K. Baumann, M. Barton
Am J Physiol Regul Integr Comp Physiol 293, R2218-R2224, 2007
Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, R. Hofmann-Lehmann, R. Minotti, M. Barton
Cardiovasc Res 73, 368-375, 2007
Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007
Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society Online Publication Sept 3, 2007
Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis
T. Traupe, M. Keller, E. Fojtu, I. Bhattacharya, M. Lang, H.R. Ha, W. Jochum, A.L. Mundy, M. Barton
J Cardiovasc Pharmacol 50, 578-584, 2007
Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling
M.R. Meyer, E. Haas, M. Barton
Hypertension 47, 1019-26, 2006
Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus
P.C. Nett, J. Ortmann, J. Celeiro, E. Haas, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Life Sci 78, 2213-2218, 2006
Recent developments on endothelin antagonists as immunomodulatory drugs - from infection to transplantation medicine.
P.C. Nett, M.M. Teixeira, D. Candinas, M. Barton
Recent Pat Cardiovasc Drug Discov 1, 233-244, 2006
Role of endothelin receptors for renal protection and survival in hypertension. waiting for clinical trials
M. Barton, J.J. Mullins, M.A. Bailey, M. Kretzler
Hypertension 48, 834-837, 2006
Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R. Hofmann-Lehmann, K. Baumann, M. Barton
J Cardiovasc Pharmacol 47, 456-462, 2006
Beneficial cardiovascular effects of endothelin ETA receptor blockade in established long-term heart failure after myocardial infarction
D. Vetter, S.G. Shaw, R.P. Brandes, K. Münter, W. Vetter, M. Barton
Exp Biol Med (Maywood) 231, 857-60, 2006
Upregulation of endothelin converting enzyme-1 in host liver during chronic cardiac allograft rejection
T. Lattmann, J. Ortmann, S. Horber, S.G. Shaw, M. Hein, M. Barton
Exp Biol Med (Maywood) 231, 899-901, 2006
Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg 44, 993-997, 2006
Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Exp Biol Med (Maywood) 231, 1030-1033, 2006
Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice
M. Kretz, A.L. Mundy, C.C. Widmer, M. Barton
J Cardiovasc Pharmacol 48, 30-33, 2006
Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity
E.R. Waelti, M. Barton
Pharmacology 78, 198-201, 2006
Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins
G. Muller, R.A. Catar, B. Niemann, M. Barton, L. Kneels, M. Wendel, H. Morawietz
Exp Biol Med (Maywood) 231, 766-771, 2006
Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries
C.C. Widmer, A.L. Mundy, M. Kretz, M. Barton
Exp Biol Med (Maywood) 231, 777-781, 2006
Postural effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K. Franzeck
J Vasc Res 43, 321-326, 2006
Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005
Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005
Endothelin differently regulates interleukin-1 beta and interleukin-1 receptor antagonist expression In non-cardiac organs of the host during chronic cardiac allograft rejection
T Lattmann, M Hein, MM Teixeira, W Vetter, M Barton
Transplant International 18, 90, 2005
Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005
Aging and biomedicine 2005: Where should we go from here?
M. Barton
Cardiovasc Res 66, 187-189, 2005
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc Res 66 , 295- 306, 2005
Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet β-cells.
J. Ortmann, P.C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R. Hofmann-Lehmann, E. Haas, B. Frank, L.M. Terraciano, M. Barton
Biochem Biophys Res Commun 334, 689-695, 2005
Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells
B. Niemann, S. Rohrbach, R.A. Catar, G. Muller, M. Barton, H. Morawietz
Biochem Biophys Res Commun 334, 747-753, 2005
Cardiovascular Research Spotlight Issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005
Endothelin in the microvasculature
M. Barton
In: Microvascular Research: Biology and Pathobiology (D. Shepro, Ed.), Academic Press, San Diego, pp 5-12, 2005
Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling
T. Lattmann, M. Hein, S. Horber, J. Ortmann, M.M. Teixeira, D.G. Souza, E. Haas, L. Tornillo, K. Münter, W. Vetter, M. Barton
Am J Transplant 5, 1042-1049, 2005
Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N. Parekh, T. Traupe, M. Lange, T. Lattmann, M. Barton
Hypertension 44, 974-981, 2004
Protective Role of ETA endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats
E.R.S. Camargos, L.L.V. Rocha, M.A. Rachid, A.P. Almeida, A.J. Ferreira, A.L. Teixeira-Jr, E. Chiari, M. Barton, M.M. Teixeira, C.R.S. Machado
Microbes Infect 6, 650-656, 2004
Amiodarone acutely inhibits vascular activity of endothelin-converting enzymes
T. Traupe, M. Lang, J. Ortmann, M. Keller, E. Fojtu, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S113-S116, 2004
Upregulation of vascular ETB receptor gene expression after chronic ETA receptor blockade in prediabetic NOD mice
J. Ortmann, T. Traupe, P. Nett, J. Celeiro, R. Hofmann-Lehmann, M. Lange, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S105-S108, 2004
In-vivo interactions of nitric oxide and endothelin
T. Lattmann, W. Vetter, M. Barton
J Hypertens 22, 1839-1840, 2004
Protease-activated receptors and EDHF: the icing on the cake?
T. Traupe and M. Barton
Cardiovasc Res 61, 645-647, 2004
Einfluss Postmenopausaler Hormonsubstitution mit konjugierten equinen Oestrogenen und Medroxyprogesteronazetat auf das kardiovaskuläre Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz Rundsch Med Prax 93, 904-914, 2004
Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth
L. Emmanuele, J. Ortmann, T. Doerflinger, T. Traupe, M. Barton
Biochem Biophys Res Commun 302, 67-72, 2003
Obesity-associated activation of angiotensin and endothelin in the cardiovascular system
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T. Traupe
Int J Biochem Cell Biol 35, 826-837, 2003
Cardiovascular consequences of the obesity pandemic: need for action
M. Barton, J. Furrer
Exp Opin Invest Drugs 12, 1757-1759, 2003
Endothelin, hypercholesterolemia and atherosclerosis
M. Barton, T. Traupe, C.C. Haudenschild
Coron Artery Dis 14, 477-490, 2003
Endothelial therapy of atherosclerosis and its risk factors
T. Traupe, J. Ortmann, K. Münter, M. Barton
Current Vasc Pharmacol 1, 111-121, 2003
Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression
T. Traupe, M. Lang, W. Goettsch, K. Münter, H. Morawietz, W. Vetter, M. Barton
J Hypertens 20, 2239-2245, 2002
Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002
Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.). Proceedings of the 5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002
Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002
Effects of obesity on endothelium-dependent reactivity during acute nitric oxide inhibition: modulatory role of endothelin
T. Traupe, L.V. d'Uscio, K. Muenter, H. Morawietz, W. Vetter, M. Barton
Clin Sci (Lond) 103 (Suppl. 48), 13S-15S, 2002
Role of endothelin during experimental Trypanosoma cruzi infection in rats
E.R.S. Camargos, C.R.S. Machado, A.L. Teixeira-Jr, L.L.V. Rocha, A.J. Ferreira, A.P. Almeida, M. Barton, M.M.Teixeira
Clin Sci (Lond) 103 (Suppl. 48), 64S-67S, 2002
Increased expression of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Clin Sci (Lond) 103 (Suppl. 48), 237S-240S, 2002
Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002
Native LDL induces proliferation of human vascular smooth muscle cells via a redox-mediated activation of ERK1/2 mitogen-activated protein kinases
R. Locher, R.P. Brandes, W. Vetter, M. Barton
Hypertension 39 (Part 2), 645-50, 2002
Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein
R. Locher, L. Emmanuele, P.M. Suter, W. Vetter, M. Barton
Eur J Pharmacol 434, 1-7, 2002
Oral contraceptives and the risk of thrombosis and atherosclerosis
M. Barton, R.K. Dubey, T. Traupe
Exp Opin Invest Drugs 11, 329-332, 2002
Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002
Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Biochem Biophys Res Commun 295, 1057-61, 2002
Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103 (S), 438S-441S, 2002
Postmenopausal estrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001
Endothelin receptor blockade and nitric oxide bioactivity
M. Barton, B. Glodny
Cardiovasc Res 52, 161-163, 2001
The therapeutic potential of endothelin receptor antagonists in cardiovascular disease
M. Barton, W. Kiowski
Curr Hypertens Rep 3, 322-330, 2001
Endothelin and cardiac arrhythmias: do endothelin antagonists have therapeutic potential as antiarrhythmic drugs?
F. Duru, M. Barton, T.F. Luscher, R. Candinas
Cardiovasc Res 49, 272-280, 2001
Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001
Endothelium and atherogenesis: endothelial therapy revisited
M. Barton, C.C. Haudenschild
J Cardiovasc Pharmacol 38 (Suppl. 2), S23-S25, 2001
Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001
Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin
M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H. Hillen, C.C. Haudenschild, J.E. Krieger, K. Münter, T. Lattmann, T.F. Luscher, S. Shaw
Hypertension 35, 329-336, 2000
Endothelin and endothelin antagonists – therapeutic considerations for a novel class of cardiovascular drugs
T.F. Luscher, M. Barton
Circulation 102, 2434-2440, 2000
Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis
M. Barton, I. Vos, S. Shaw, P. Boer, L.V. d'Uscio, H.-J. Gröne, T.J. Rabelink, T. Lattmann, P. Moreau, T.F. Luscher
J Am Soc Nephrol 11, 835-846, 2000
Oestrogensubstitutionstherapie und Arteriosklerose - Pathophysiologie und therapeutische Implikationen
M. Barton
J Menopause 7, 12-15, 2000
Hypertension, diabetes mellitus, hypercholesterolemia and endothelin B receptor-mediated renal nitric oxide release
M. Barton, L.V. d'Uscio
Circulation 101; e228-e229, 2000
Sex and NO - beyond regulation of vasomotor tone
M. Barton
Cardiovasc Res 46, 20-23, 2000
Assessment of coronary flow reserve by contrast-enhanced second harmonic echo Doppler
R. Jenni, A. Linka, M. Barton
Circulation 101, e100, 2000
Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S. Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation 102, III188 -III193, 2000
Doppler mirror image artifacts mimicking mitral regurgitation in patients with mechanical bileaflet mitral valve prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R. Jenni
Eur Heart J Cardiovasc Imag 1, 138-43, 2000
Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three dimensional mapping
F. Duru, M. Barton, R. Candinas
Cardiovasc Res 46, 604-605, 2000
Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade
M. Burkhardt, M. Barton, S.G. Shaw
J Hypertens 18, 273-279, 2000
Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics
M. Barton
Curr Hypertens Reports 2, 84-91, 2000
Endothelin und Atherosklerose. Kausale Bedeutung und therapeutische Implikationen
M. Barton
Kardiovask Med 3, 13-18, 2000
Endothelin in atherosclerosis: importance of risk factors and therapeutic implications
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
J Cardiovasc Pharmacol 35 (4 suppl 2), S55-S59, 2000
Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease
M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S153-S156, 2000
Endothelin regulates angiotensin-converting enzyme in the mouse kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz, L.V. d'Uscio, T. Lattmann, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S244-S247, 2000
Endothelin antagonists for hypertension and renal disease
M. Barton, T.F. Luscher
Curr Opin Nephrol Hypertens 8, 549-556, 1999
Endothelial dysfunction in acute renal faiulre: role of circulating and tissue endothelin-1
F. Ruschitzka, S. Shaw, D. Gygi, G. Noll, M. Barton, T.F. Luscher
J Am Soc Nephrol 10, 953-962, 1999
Endothelial dysfunction in the aorta of transgenic rats harboring the mouse ren-2 gene
U.A. Arnet, D. Novosel, M. Barton, G. Noll, D. Ganten, T.F. Luscher
Endothelium 6, 175-184, 1999
Estrogen and vascular resistance
M. Barton, T.F. Luscher
Curr Opin Endocrinol Diabet 6, 218-224, 1999
Vascular effects of estrogens: rapid actions, novel mechanisms, and potential therapeutic implications
M. Barton
Acta Pharmacol Sin 20, 682-690, 1999
Endothelin in heart failure
G. Sutsch, M. Barton
Curr Hypertens Reports 1, 62-68, 1999
Vascular effects of estrogen
E. Wight, M. Barton, E. Espinosa, T. Luscher.
In: Menopause and the Heart (T.B. Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia; 1, pp 1-7, 1999
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
M. Barton, C.C. Haudenschild, L.V. d`Uscio, S. Shaw, K. Münter, T.F. Luscher
Proc Natl Acad Sci U.S.A. 95, 14367-14372, 1998
ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
M. Barton, L.V. d`Uscio, S. Shaw, P. Meyer, P. Moreau, and T.F. Luscher
Hypertension 31, 499-504, 1998
Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase. Role of blood pressure and endothelial function
L.V. d`Uscio, S. Shaw, M. Barton, T.F. Luscher
Hypertension 31, 1305-1310, 1998
Endothelial aging - a determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July 23-24, 1998
Cardiovasc Drug Rev 3, 300-311, 1998
Salt wars
M. Barton, T.F. Luscher, T.J. Rabelink
Science 281, 1961, 1998
Endothelial vasoconstrictor prostanoids, vascular reactivity, and acute renal failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller, T.F. Luscher
Kidney Int 67, S199-S201, 1998
Differential modulation of the renal myocardial endothelin system by angiotensin II in vivo: effects of chronic selective ETA receptor blockade
M. Barton, S. Shaw, L. V. d'Uscio, P. Moreau, T.F. Luscher
J Cardiovasc Pharmacol 31 (Suppl 1), S265-S268, 1998
17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998
Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries
M. Barton, J.L. Bény, L.V. d`Uscio, T. Wyss, G. Noll, T.F. Luscher
J Cardiovasc Pharmacol 31, 377-383, 1998
Biology of the endothelium
T.F. Luscher, M. Barton
Clin Cardiol 20 (Suppl. II), 3-10, 1997
Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation
M. Barton, S. Shaw, L.V. d`Uscio, P. Moreau, T.F. Luscher
Biochem Biophys Res Commun 238, 861-865, 1997
Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade
L.V. d'Uscio, M. Barton, S. Shaw, P. Moreau, T.F. Luscher
Hypertension 30, 905-911, 1997
Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist
P. Moreau, L. V. d'Uscio, S. Shaw, H. Takase, M. Barton, T.F. Luscher
Circulation 96, 1593-1597, 1997
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
L.V. d`Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, T.F. Luscher
Hypertension 29, 435-441, 1997
Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and histochemical techniques
R.P. Brandes, M. Barton, K.M.H. Philippens, G. Schweitzer, A. Mügge
J Physiol (Lond) 500, 331-342, 1997
The endothelium as therapeutic target for atherosclerosis. Importance of ACE inhibition and cholesterol lowering
M. Barton, T.F. Luscher
Thoraxcenter J 9, 12-19, 1997
Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F. Luscher
Hypertension 30, 817-824, 1997
Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997
Gefässprotektion durch Oestrogene. Wirkungen in vitro und in vivo - Mechanismen und klinische Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F. Luscher
Schweiz Rundsch Med (PRAXIS) 86, 129-137, 1997
Endothelin-1 and endothelin-3 are differently modulated during hepatic regeneration after partial hepatectomy
S Shaw, A Wheatley, H Rieder, L Kuznetsove, H Lagger, YY Zhang, M Barton, T Luscher
Jap J Pharmacol 75, 133, 1997
17β-Oestradiol inhibits growth of human vascular smooth muscle: similar effects in cells from females and males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F. Luscher
J Cardiovasc Pharmacol 28 (Suppl. 5), S34-S39, 1996
Wirkungen natürlicher Oestrogene auf die Gefässwand: Molekulare Mechanismen und klinische Implikationen
T.F. Luscher, M. Barton, E. Wight, E. Espinosa, Z. Yang
Schweiz Med Wschr 126, 1748-1755, 1996
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino, G. Noll, T. Malinski, T.F. Luscher
J Clin Invest 98, 899-905, 1996
Contractions induced by histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human arteries in vitro
A Mügge, M Barton, M Riedel, PR Lichtlen
Circulation 92 (Suppl. I), 431, 1995
Intact vascular endothelial and smooth muscle cells are producing superoxide anions - evidence from histochemical and chemiluminescence techniques.
R Brandes, M Barton, A Dwenger, A Mügge
Circulation 92 (8), 1861, 1995
Acute effects of 17β-oestradiol on vascular reactivity of isolated human coronary arteries
A Mügge, M Barton, M Riedel, PR Lichtlen
Eur Heart J 16 (Suppl), 496, 1995
Wirkung von 17β-Oestradiol auf die Endothel-abhängige Relaxation von menschlichen Mammaria- und Koronararterien
M Barton, M Mügge, Andreas, Riedel, PR Lichtlen
Z Kardiol 84 (Suppl. 1), 44, 1995
Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993
Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993
Estrogen dilates human coronary arteries in vitro by an increase in cyclic GMP and cyclic AMP smooth muscle content
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Eur Heart J 14, 16, 1993
17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993
Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992
Sex and sex steroids as determinants of cardiovascular risk
A. Cignarella, C. Bolego, M. Barton
Steroids 2024
Post-transcriptional and epigenetic regulation of estrogen signaling
A. Cignarella, C. Boscaro, M. Albiero, C. Bolego, M. Barton
J Pharmacol Exp Ther 386, 288-297, 2023
The G protein-coupled estrogen receptor GPER in physiology and disease - an update
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 19, 407-424, 2023
Consensus Document: Challenges in the evaluation of endothelial cell function - a statement from the European Society of Hypertension Working Group on Endothelins and Endothelial Factors
G.P. Rossi, M. Barton, N. Dhaun, D. Rizzoni, T.M. Seccia
J Hypertens 41, 369-379, 2023
Endothelium and endothelin: regulators of arterial stiffness and fibrinolysis in ANCA-associated vasculitis
M. Barton
Kidney Int 102, 963-966, 2022
Efficacy and safety of angiogenesis inhibitors: sex differences and current challenges
A. Cignarella, G.P. Fadini, C. Bolego, L. Trevisi, C. Boscaro, V. Sanga, T.M. Seccia, A. Rosato, G.P. Rossi, M. Barton
Cardiovasc Res 118, 988-1003, 2022 (Editor's Choice)
Serum from patients with severe alcoholic liver cirrhosis inhibits proliferation and migration of human coronary artery smooth muscle cells
M. Mechelinck, M. Peschel, M. A. Habigt, D. Kroy, M. Lehrke, M. J. Helmedag, R. Rossaint, M. Barton, M. Hein
J Clin Med 10, 5471, 2021
Paul M. Vanhoutte: Mind, Mensch, and Mentor
M Barton.
J Cardiovasc Pharmacol 78, 91, 2021
In Memoriam: Christian Sauter
H. Ruh, M. Barton
Endocrin Metab Sci 5, 100115, 2021
Steroid Hormones and Receptors in Health and Disease: A Research Conference Co-Organized by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH), May 25-27, 2021
M. Barton, D.E. Frigo, Z. Madak-Erdogan, F. Mauvais-Jarvis, E.R. Prossnitz
FASEB J 35, e21858, 2021
Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: a large-scale, cross-sectional study in primary care
Y. Rachamin, T. Grischott, T. Rosemann, M.R. Meyer.
Atherosclerosis 324, 141-147, 2021
Chronic coronary syndromes in women
M.R. Meyer
Mayo Clinic Proceedings 96, 1058-1070, 2021
Obesity, diabetes and cardiovascular risk: how to disrupt a vicious circle
C. Cardillo, M. Barton
Endocrin Metab Sci 2, 100081, 2021
Efficacy and safety of abbreviated eptifibatide treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
F. Fischer, S. Buxy, D.J. Kurz , F.R. Eberli, O. Senn, R. Zbinden, U. Held, M.R. Meyer.
Am J Cardiol 139,15-21, 2021
Exercise is medicine – key to cardiovascular disease and diabetes prevention
M. Barton, C. Cardillo
Cardiovasc Res 117, 360-364, 2021
Role of perivascular adipose tissue for sex differences in coronary artery disease and spontaneous coronary artery dissection (SCAD)
M.R. Meyer, M. Barton
Endocrin Metab Sci 2, 100068, 2021
Differences in presentation and clinical outcomes between left or right bundle branch block and ST segment elevation in patients with acute myocardial infarction
M.R. Meyer, D. Radovanovic, G. Pedrazzini, H. Rickli, M. Roffi, T. Rosemann, F.R. Eberli, D.J. Kurz
Eur Heart J Acute Cardiovasc Care 9, 848-856, 2020
In memoriam: Tomoh Masaki
N. Emoto, M. Yanagisawa, M. Barton
Hypertension 76, 1664-1666, 2020
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
G.P. Rossi, V. Sanga, M. Barton
eLife 9, e57278, 2020
Heart failure with preserved ejection fraction in women - new clues to causes and treatment
M. Barton, M.R. Meyer
JACC Basic Transl Sci 5, 296-299, 2020
Early life stress determines insulin signaling in adulthood
M. Barton, E.R. Prossnitz
J Physiol 598, 427-428, 2020
Linking regulation of nitric oxide to endothelin-1: the Yin and Yang of vascular tone in the atherosclerotic plaque
R.M. Gupta, P. Libby, M. Barton
Atherosclerosis 292, 201-203, 2020
In memoriam: Paul M. Vanhoutte
M. Barton, C. Cardillo
J Physiol 597, 5731-5737, 2019
Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019
(featured in: Hypertension Editors’ Picks: Pulmonary Hypertension
Hypertension 77, e1–e10, 2021)
Nox1 downregulators: a new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019
Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia (letter)
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science 365, eaav9518, 2019
Primum non nocere: why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019
Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population.
Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T
Clin Ther 41, 107-117, 2019
Permissive role for GPER in arterial hypertension
M. Barton, M.R. Meyer
Hypertension 73, e9-e10, 2019
HuR-ry up: How hydrogen sulfide protects against atherosclerosis
M. Barton, M.R. Meyer
Circulation 139, 155-118, 2019
Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 8, 283-290, 2019
Self-experimentation and serendipity: how cardiac catheterization led the way to coronary balloon angioplasty
M. Barton
BMJ 363:k5006, 2018
GPER is required for age-dependent albuminuria and glomerulosclerosis: evidence for its role in podocyte injury and mesangial Nox1 regulation
M.R. Meyer, C. Daniel, C.D. Woods, G. Sharma, N.C. Fredette, K. Amann, M. Barton, E.R. Prossnitz
Hypertension 72 (suppl), P261, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018
Hypertrophe und dilatative Kardiomyopathie
M.R. Meyer, F.R. Eberli.
Swiss Medical Forum 18, 168–177, 2018
In Memoriam: Sidney George Shaw, DPhil (1948-2017)
M. Barton, H. J. Little, R.D. Vaughn-Jones, S. Daniels, M.R. Dashwood, M.R. Dashwood, J.C. Tsui.
Physiol Res 67 (Suppl. 1), S-27-S35, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. a Joint Consensus Statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertens 36, 462-471, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. a Joint Consensus Statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertens 36, 451-461, 2018
Role of GPER in estrogen-dependent nitric oxide formation and vasodilation.
N.C. Fredette, M.R. Meyer, E.R Prossnitz
J Steroid Biochem Mol Biol 76, 65-72, 2018
GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton
J Steroid Biochem Mol Biol 176, 82-87, 2018
Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018
Iron substitution in the treatment of chronic heart failure
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 23; w14453, 2017
Paradoxical lack of increase in endothelin-1 levels in obese mice – possible role of endothelin-B receptors
O. Baretella, S.K. Chung, A. Xu, P.M Vanhoutte
Acta Pharmacologica Sinica 38, 1699–1700, 2017
Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017
GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017
Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016
Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016
Efficacy and safety of transcatheter closure in adults with large or small atrial septal defects
M.R. Meyer, D.J. Kurz, A.M. Bernheim, O. Kretschmar. F.R. Eberli
Springerplus 5, 1841, 2016
Obesity causes lymphatic vascular injury: time for clinical translation
Barton M, Husmann M.
J Physiol 594, 6807-6808, 2016
Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016
Not lost in translation: emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016
GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016
Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016
G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015
Erratum: G protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 5, 13510, 2015
Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015
Nicolaus Copernicus and the rapid vascular responses to aldosterone
M. Barton, M.R. Meyer
Trends Endocrinol Metab 26, 396-398, 2015
Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015
Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015
Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014
Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 4, 7564, 2014
In memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014
Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014
25 Years of endothelin research: the next generation
N. Emoto, N. Vignon-Zellweger, R.A. Lopes, J. Cacioppo, L. Debiens, D. Kamato, T. Leurgans, R. Moorhouse, J. Straube, R. Wurm, S. Heiden, A. Ergul, M. Yanagisawa, M. Barton
Life Sci 118, 77-86, 2014
Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014
Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014
Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretella, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci 118, 206-212, 2014
Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz
Life Sci 118, 226-231, 2014
Estrogen biology: new insights on GPER function and clinical opportunities
E.R Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014
Regulation of vascular smooth muscle tone by Adipose-Derived Contracting Factor
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
PLoS ONE 8, e79245, 2013
Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013
Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz
J Cardiovasc Pharmacol 62, 22-25, 2013
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013
Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton
Curr Opin Pharmacol 13, 149-153, 2013
Cholesterol and atherosclerosis: modulation by estrogen
M. Barton
Curr Opin Lipidol 24, 214-220, 2013
Themed section: endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013
Endothelin XII - Editorial
M. Barton, M. Yanagisawa, P.M. Vanhoutte, T. Masaki
Life Sci 91, 449-451, 2012
The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
M. Barton, A.P. Davenport
Life Sci 91, 462-465, 2012
The First Tomoh Masaki Award (2011)
M. Barton, N. Emoto, T. Miyauchi
Life Sci 91, 466-469, 2012
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton
Life Sci 91, 528-539, 2012
The future of endothelin research: scientific mentoring and beyond
M. Barton, D.M. Pollock
Life Sci 91, 470-474, 2012
GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz
Life Sci 91, 623-627, 2012
Testosterone and secondary hypertension: new pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer
Hypertension 59, 1011-1103, 2012
Position paper: the membrane estrogen receptor GPER - clues and questions
M. Barton
Steroids 77, 925-242, 2012
Endothelin and the podocyte
M. Barton, P.L. Tharaux
Clin Kidney J 5, 17-27, 2012
Endothelin receptor antagonists in cardiovascular medicine: challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012
Deletion of the G protein-coupled estrogen receptor increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L. Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz
Hypertension 59, 507-512, 2012
Childhood obesity: a life-long health risk
M. Barton
Acta Pharmacol Sin 33, 189-193, 2012
Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Endothelin in renal physiology and disease
Contrib Nephrol 172 (M. Barton, D.E. Kohan, Eds), Karger, Basel, 1-266, 2011
The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton
Vascul Pharmacol 55, 17-25, 2011
Endothelin antagonists in clinical trials: lessons learned
M. Barton, D.E. Kohan
Contrib Nephrol 172, 255-260, 2011
Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux
Contrib Nephrol 172, 120-138, 2011
Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton
Contrib Nephrol 172, 210-222, 2011
Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011
GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton
Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011
Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011
The discovery of endothelium-dependent contraction: the legacy of Paul M. Vanhoutte
M. Barton
Pharmacol Res 63, 455-462, 2011
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010
Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflügers Arch Eur J Physiol 460, 825-837, 2010
Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010
Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010
Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010
Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010
Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
ERα, ERβ, and gpER: novel aspects of estrogen receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83, 605-610, 2009
Non-genomic regulation of vascular cell function and growth by estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 308, 9-16, 2009
Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins Other Lipid Mediat 89, 89-97, 2009
Regulatory role of G protein coupled estrogen receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C. Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut, R. Minotti, M.R. Meyer, K. Amann, E. Ammann, A. Perez-Dominguez, M. Genoni, D.J. Clegg, N.J. Dun, T.C. Resta, E.R. Prossnitz, M. Barton
Circ Res 104, 288-291, 2009
Getting radical about obesity: new links between fat and heart disease
M. Barton, E. Haas, I. Bhattacharya
Arterioscler Thromb Vasc Biol 29, 447-448, 2009
Morbus Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B. Senn
Swiss Medical Forum 9, 487-488, 2009
Endothelin - Twenty years from discovery to therapy
Matthias Barton, Masashi Yanagisawa
Can J Physiol Pharmacol 86, 485-498, 2008
Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008
Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend Med 5 (Suppl. A), S19-S33, 2008
Regional heterogeneity of functional changes in conduit arteries after high-fat diet
I. Bhattacharya, A.L. Mundy, C.C. Widmer, M. Kretz, M. Barton
Obesity (Silver Spring) 16, 743-748, 2008
Schwere Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I. Bopp-Kistler
Praxis (Bern 1994) 97, 1137-1141, 2008
Fat intake and cardiovascular response
M. Damjanovic, M. Barton
Curr Hypertens Rep 10, 25-31 2008
Inflammation and atherosclerosis
M. Barton, R. Minotti, E. Haas
Circ Res 101, 750-751, 2007
Selective activation of G protein-coupled estrogen receptor GPR30 inhibits vasoconstriction and induces vascular smooth muscle cell ERK1/2 phosphorylation
I. Bhattacharya, M. Damjanovic, S. Hirsiger, E. Haas, A. Gut, L. Mueller-Guerre, R. Henggeler, R. Minotti, E.R. Prossnitz, M. Barton
Circulation 116, II74, 2007
Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007
WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J Rapid Response, e-pub August 28, 2007
Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Distinct roles of estrogen receptors α and β mediating acute vasodilatation of epicardial coronary arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, M. Barton
Hypertension 49, 1364-1370, 2007
Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007
Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007
Impaired vascular function in normoglycemic mice prone to autoimmune diabetes: role of nitric oxide
T. Traupe, P.C. Nett, B. Frank, L. Tornillo, R. Hofmann-Lehmann, L.M. Terracciano, M. Barton
Eur J Pharmacol 557,161-167, 2007
Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007
Vaskuläre Interaktion zwischen Insulin und LDL Cholesterin
E. Haas, R. Minotti, C. Raselli, A. Hoehn, M. Barton
Dtsch Med Wochensch 132, 20, 2007
Endothelin stimulates vascular hydroxyl radical formation: effect of obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K. Baumann, M. Barton
Am J Physiol Regul Integr Comp Physiol 293, R2218-R2224, 2007
Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, R. Hofmann-Lehmann, R. Minotti, M. Barton
Cardiovasc Res 73, 368-375, 2007
Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007
Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society Online Publication Sept 3, 2007
Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis
T. Traupe, M. Keller, E. Fojtu, I. Bhattacharya, M. Lang, H.R. Ha, W. Jochum, A.L. Mundy, M. Barton
J Cardiovasc Pharmacol 50, 578-584, 2007
Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling
M.R. Meyer, E. Haas, M. Barton
Hypertension 47, 1019-26, 2006
Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus
P.C. Nett, J. Ortmann, J. Celeiro, E. Haas, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Life Sci 78, 2213-2218, 2006
Recent developments on endothelin antagonists as immunomodulatory drugs - from infection to transplantation medicine.
P.C. Nett, M.M. Teixeira, D. Candinas, M. Barton
Recent Pat Cardiovasc Drug Discov 1, 233-244, 2006
Role of endothelin receptors for renal protection and survival in hypertension. waiting for clinical trials
M. Barton, J.J. Mullins, M.A. Bailey, M. Kretzler
Hypertension 48, 834-837, 2006
Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R. Hofmann-Lehmann, K. Baumann, M. Barton
J Cardiovasc Pharmacol 47, 456-462, 2006
Beneficial cardiovascular effects of endothelin ETA receptor blockade in established long-term heart failure after myocardial infarction
D. Vetter, S.G. Shaw, R.P. Brandes, K. Münter, W. Vetter, M. Barton
Exp Biol Med (Maywood) 231, 857-60, 2006
Upregulation of endothelin converting enzyme-1 in host liver during chronic cardiac allograft rejection
T. Lattmann, J. Ortmann, S. Horber, S.G. Shaw, M. Hein, M. Barton
Exp Biol Med (Maywood) 231, 899-901, 2006
Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg 44, 993-997, 2006
Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Exp Biol Med (Maywood) 231, 1030-1033, 2006
Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice
M. Kretz, A.L. Mundy, C.C. Widmer, M. Barton
J Cardiovasc Pharmacol 48, 30-33, 2006
Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity
E.R. Waelti, M. Barton
Pharmacology 78, 198-201, 2006
Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins
G. Muller, R.A. Catar, B. Niemann, M. Barton, L. Kneels, M. Wendel, H. Morawietz
Exp Biol Med (Maywood) 231, 766-771, 2006
Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries
C.C. Widmer, A.L. Mundy, M. Kretz, M. Barton
Exp Biol Med (Maywood) 231, 777-781, 2006
Postural effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K. Franzeck
J Vasc Res 43, 321-326, 2006
Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005
Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005
Endothelin differently regulates interleukin-1 beta and interleukin-1 receptor antagonist expression In non-cardiac organs of the host during chronic cardiac allograft rejection
T Lattmann, M Hein, MM Teixeira, W Vetter, M Barton
Transplant International 18, 90, 2005
Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005
Aging and biomedicine 2005: Where should we go from here?
M. Barton
Cardiovasc Res 66, 187-189, 2005
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc Res 66 , 295- 306, 2005
Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet β-cells.
J. Ortmann, P.C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R. Hofmann-Lehmann, E. Haas, B. Frank, L.M. Terraciano, M. Barton
Biochem Biophys Res Commun 334, 689-695, 2005
Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells
B. Niemann, S. Rohrbach, R.A. Catar, G. Muller, M. Barton, H. Morawietz
Biochem Biophys Res Commun 334, 747-753, 2005
Cardiovascular Research Spotlight Issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005
Endothelin in the microvasculature
M. Barton
In: Microvascular Research: Biology and Pathobiology (D. Shepro, Ed.), Academic Press, San Diego, pp 5-12, 2005
Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling
T. Lattmann, M. Hein, S. Horber, J. Ortmann, M.M. Teixeira, D.G. Souza, E. Haas, L. Tornillo, K. Münter, W. Vetter, M. Barton
Am J Transplant 5, 1042-1049, 2005
Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N. Parekh, T. Traupe, M. Lange, T. Lattmann, M. Barton
Hypertension 44, 974-981, 2004
Protective Role of ETA endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats
E.R.S. Camargos, L.L.V. Rocha, M.A. Rachid, A.P. Almeida, A.J. Ferreira, A.L. Teixeira-Jr, E. Chiari, M. Barton, M.M. Teixeira, C.R.S. Machado
Microbes Infect 6, 650-656, 2004
Amiodarone acutely inhibits vascular activity of endothelin-converting enzymes
T. Traupe, M. Lang, J. Ortmann, M. Keller, E. Fojtu, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S113-S116, 2004
Upregulation of vascular ETB receptor gene expression after chronic ETA receptor blockade in prediabetic NOD mice
J. Ortmann, T. Traupe, P. Nett, J. Celeiro, R. Hofmann-Lehmann, M. Lange, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S105-S108, 2004
In-vivo interactions of nitric oxide and endothelin
T. Lattmann, W. Vetter, M. Barton
J Hypertens 22, 1839-1840, 2004
Protease-activated receptors and EDHF: the icing on the cake?
T. Traupe and M. Barton
Cardiovasc Res 61, 645-647, 2004
Einfluss Postmenopausaler Hormonsubstitution mit konjugierten equinen Oestrogenen und Medroxyprogesteronazetat auf das kardiovaskuläre Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz Rundsch Med Prax 93, 904-914, 2004
Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth
L. Emmanuele, J. Ortmann, T. Doerflinger, T. Traupe, M. Barton
Biochem Biophys Res Commun 302, 67-72, 2003
Obesity-associated activation of angiotensin and endothelin in the cardiovascular system
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T. Traupe
Int J Biochem Cell Biol 35, 826-837, 2003
Cardiovascular consequences of the obesity pandemic: need for action
M. Barton, J. Furrer
Exp Opin Invest Drugs 12, 1757-1759, 2003
Endothelin, hypercholesterolemia and atherosclerosis
M. Barton, T. Traupe, C.C. Haudenschild
Coron Artery Dis 14, 477-490, 2003
Endothelial therapy of atherosclerosis and its risk factors
T. Traupe, J. Ortmann, K. Münter, M. Barton
Current Vasc Pharmacol 1, 111-121, 2003
Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression
T. Traupe, M. Lang, W. Goettsch, K. Münter, H. Morawietz, W. Vetter, M. Barton
J Hypertens 20, 2239-2245, 2002
Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002
Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.). Proceedings of the 5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002
Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002
Effects of obesity on endothelium-dependent reactivity during acute nitric oxide inhibition: modulatory role of endothelin
T. Traupe, L.V. d'Uscio, K. Muenter, H. Morawietz, W. Vetter, M. Barton
Clin Sci (Lond) 103 (Suppl. 48), 13S-15S, 2002
Role of endothelin during experimental Trypanosoma cruzi infection in rats
E.R.S. Camargos, C.R.S. Machado, A.L. Teixeira-Jr, L.L.V. Rocha, A.J. Ferreira, A.P. Almeida, M. Barton, M.M.Teixeira
Clin Sci (Lond) 103 (Suppl. 48), 64S-67S, 2002
Increased expression of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Clin Sci (Lond) 103 (Suppl. 48), 237S-240S, 2002
Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002
Native LDL induces proliferation of human vascular smooth muscle cells via a redox-mediated activation of ERK1/2 mitogen-activated protein kinases
R. Locher, R.P. Brandes, W. Vetter, M. Barton
Hypertension 39 (Part 2), 645-50, 2002
Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein
R. Locher, L. Emmanuele, P.M. Suter, W. Vetter, M. Barton
Eur J Pharmacol 434, 1-7, 2002
Oral contraceptives and the risk of thrombosis and atherosclerosis
M. Barton, R.K. Dubey, T. Traupe
Exp Opin Invest Drugs 11, 329-332, 2002
Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002
Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Biochem Biophys Res Commun 295, 1057-61, 2002
Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103 (S), 438S-441S, 2002
Postmenopausal estrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001
Endothelin receptor blockade and nitric oxide bioactivity
M. Barton, B. Glodny
Cardiovasc Res 52, 161-163, 2001
The therapeutic potential of endothelin receptor antagonists in cardiovascular disease
M. Barton, W. Kiowski
Curr Hypertens Rep 3, 322-330, 2001
Endothelin and cardiac arrhythmias: do endothelin antagonists have therapeutic potential as antiarrhythmic drugs?
F. Duru, M. Barton, T.F. Luscher, R. Candinas
Cardiovasc Res 49, 272-280, 2001
Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001
Endothelium and atherogenesis: endothelial therapy revisited
M. Barton, C.C. Haudenschild
J Cardiovasc Pharmacol 38 (Suppl. 2), S23-S25, 2001
Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001
Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin
M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H. Hillen, C.C. Haudenschild, J.E. Krieger, K. Münter, T. Lattmann, T.F. Luscher, S. Shaw
Hypertension 35, 329-336, 2000
Endothelin and endothelin antagonists – therapeutic considerations for a novel class of cardiovascular drugs
T.F. Luscher, M. Barton
Circulation 102, 2434-2440, 2000
Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis
M. Barton, I. Vos, S. Shaw, P. Boer, L.V. d'Uscio, H.-J. Gröne, T.J. Rabelink, T. Lattmann, P. Moreau, T.F. Luscher
J Am Soc Nephrol 11, 835-846, 2000
Oestrogensubstitutionstherapie und Arteriosklerose - Pathophysiologie und therapeutische Implikationen
M. Barton
J Menopause 7, 12-15, 2000
Hypertension, diabetes mellitus, hypercholesterolemia and endothelin B receptor-mediated renal nitric oxide release
M. Barton, L.V. d'Uscio
Circulation 101; e228-e229, 2000
Sex and NO - beyond regulation of vasomotor tone
M. Barton
Cardiovasc Res 46, 20-23, 2000
Assessment of coronary flow reserve by contrast-enhanced second harmonic echo Doppler
R. Jenni, A. Linka, M. Barton
Circulation 101, e100, 2000
Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S. Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation 102, III188 -III193, 2000
Doppler mirror image artifacts mimicking mitral regurgitation in patients with mechanical bileaflet mitral valve prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R. Jenni
Eur Heart J Cardiovasc Imag 1, 138-43, 2000
Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three dimensional mapping
F. Duru, M. Barton, R. Candinas
Cardiovasc Res 46, 604-605, 2000
Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade
M. Burkhardt, M. Barton, S.G. Shaw
J Hypertens 18, 273-279, 2000
Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics
M. Barton
Curr Hypertens Reports 2, 84-91, 2000
Endothelin und Atherosklerose. Kausale Bedeutung und therapeutische Implikationen
M. Barton
Kardiovask Med 3, 13-18, 2000
Endothelin in atherosclerosis: importance of risk factors and therapeutic implications
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
J Cardiovasc Pharmacol 35 (4 suppl 2), S55-S59, 2000
Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease
M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S153-S156, 2000
Endothelin regulates angiotensin-converting enzyme in the mouse kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz, L.V. d'Uscio, T. Lattmann, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S244-S247, 2000
Endothelin antagonists for hypertension and renal disease
M. Barton, T.F. Luscher
Curr Opin Nephrol Hypertens 8, 549-556, 1999
Endothelial dysfunction in acute renal faiulre: role of circulating and tissue endothelin-1
F. Ruschitzka, S. Shaw, D. Gygi, G. Noll, M. Barton, T.F. Luscher
J Am Soc Nephrol 10, 953-962, 1999
Endothelial dysfunction in the aorta of transgenic rats harboring the mouse ren-2 gene
U.A. Arnet, D. Novosel, M. Barton, G. Noll, D. Ganten, T.F. Luscher
Endothelium 6, 175-184, 1999
Estrogen and vascular resistance
M. Barton, T.F. Luscher
Curr Opin Endocrinol Diabet 6, 218-224, 1999
Vascular effects of estrogens: rapid actions, novel mechanisms, and potential therapeutic implications
M. Barton
Acta Pharmacol Sin 20, 682-690, 1999
Endothelin in heart failure
G. Sutsch, M. Barton
Curr Hypertens Reports 1, 62-68, 1999
Vascular effects of estrogen
E. Wight, M. Barton, E. Espinosa, T. Luscher.
In: Menopause and the Heart (T.B. Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia; 1, pp 1-7, 1999
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
M. Barton, C.C. Haudenschild, L.V. d`Uscio, S. Shaw, K. Münter, T.F. Luscher
Proc Natl Acad Sci U.S.A. 95, 14367-14372, 1998
ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
M. Barton, L.V. d`Uscio, S. Shaw, P. Meyer, P. Moreau, and T.F. Luscher
Hypertension 31, 499-504, 1998
Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase. Role of blood pressure and endothelial function
L.V. d`Uscio, S. Shaw, M. Barton, T.F. Luscher
Hypertension 31, 1305-1310, 1998
Endothelial aging - a determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July 23-24, 1998
Cardiovasc Drug Rev 3, 300-311, 1998
Salt wars
M. Barton, T.F. Luscher, T.J. Rabelink
Science 281, 1961, 1998
Endothelial vasoconstrictor prostanoids, vascular reactivity, and acute renal failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller, T.F. Luscher
Kidney Int 67, S199-S201, 1998
Differential modulation of the renal myocardial endothelin system by angiotensin II in vivo: effects of chronic selective ETA receptor blockade
M. Barton, S. Shaw, L. V. d'Uscio, P. Moreau, T.F. Luscher
J Cardiovasc Pharmacol 31 (Suppl 1), S265-S268, 1998
17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998
Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries
M. Barton, J.L. Bény, L.V. d`Uscio, T. Wyss, G. Noll, T.F. Luscher
J Cardiovasc Pharmacol 31, 377-383, 1998
Biology of the endothelium
T.F. Luscher, M. Barton
Clin Cardiol 20 (Suppl. II), 3-10, 1997
Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation
M. Barton, S. Shaw, L.V. d`Uscio, P. Moreau, T.F. Luscher
Biochem Biophys Res Commun 238, 861-865, 1997
Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade
L.V. d'Uscio, M. Barton, S. Shaw, P. Moreau, T.F. Luscher
Hypertension 30, 905-911, 1997
Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist
P. Moreau, L. V. d'Uscio, S. Shaw, H. Takase, M. Barton, T.F. Luscher
Circulation 96, 1593-1597, 1997
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
L.V. d`Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, T.F. Luscher
Hypertension 29, 435-441, 1997
Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and histochemical techniques
R.P. Brandes, M. Barton, K.M.H. Philippens, G. Schweitzer, A. Mügge
J Physiol (Lond) 500, 331-342, 1997
The endothelium as therapeutic target for atherosclerosis. Importance of ACE inhibition and cholesterol lowering
M. Barton, T.F. Luscher
Thoraxcenter J 9, 12-19, 1997
Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F. Luscher
Hypertension 30, 817-824, 1997
Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997
Gefässprotektion durch Oestrogene. Wirkungen in vitro und in vivo - Mechanismen und klinische Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F. Luscher
Schweiz Rundsch Med (PRAXIS) 86, 129-137, 1997
Endothelin-1 and endothelin-3 are differently modulated during hepatic regeneration after partial hepatectomy
S Shaw, A Wheatley, H Rieder, L Kuznetsove, H Lagger, YY Zhang, M Barton, T Luscher
Jap J Pharmacol 75, 133, 1997
17β-Oestradiol inhibits growth of human vascular smooth muscle: similar effects in cells from females and males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F. Luscher
J Cardiovasc Pharmacol 28 (Suppl. 5), S34-S39, 1996
Wirkungen natürlicher Oestrogene auf die Gefässwand: Molekulare Mechanismen und klinische Implikationen
T.F. Luscher, M. Barton, E. Wight, E. Espinosa, Z. Yang
Schweiz Med Wschr 126, 1748-1755, 1996
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino, G. Noll, T. Malinski, T.F. Luscher
J Clin Invest 98, 899-905, 1996
Contractions induced by histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human arteries in vitro
A Mügge, M Barton, M Riedel, PR Lichtlen
Circulation 92 (Suppl. I), 431, 1995
Intact vascular endothelial and smooth muscle cells are producing superoxide anions - evidence from histochemical and chemiluminescence techniques.
R Brandes, M Barton, A Dwenger, A Mügge
Circulation 92 (8), 1861, 1995
Acute effects of 17β-oestradiol on vascular reactivity of isolated human coronary arteries
A Mügge, M Barton, M Riedel, PR Lichtlen
Eur Heart J 16 (Suppl), 496, 1995
Wirkung von 17β-Oestradiol auf die Endothel-abhängige Relaxation von menschlichen Mammaria- und Koronararterien
M Barton, M Mügge, Andreas, Riedel, PR Lichtlen
Z Kardiol 84 (Suppl. 1), 44, 1995
Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993
Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993
Estrogen dilates human coronary arteries in vitro by an increase in cyclic GMP and cyclic AMP smooth muscle content
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Eur Heart J 14, 16, 1993
17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993
Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992